Mesenchymal stem cells: A revolution in therapeutic strategies of age-related diseases

  title={Mesenchymal stem cells: A revolution in therapeutic strategies of age-related diseases},
  author={Yan Peng and Sha Huang and Biao Cheng and Xiaohu Nie and Jirigala Enhe and Chang-jiang Feng and Xiaobing Fu},
  journal={Ageing Research Reviews},

Role of Mesenchymal Stem Cells in Counteracting Oxidative Stress—Related Neurodegeneration

Exposure to mesenchymal stem cells or their secretome can be considered as a promising therapeutic strategy to enhance antioxidant capacity and neurotrophin expression while inhibiting pro-inflammatory cytokine secretion, which are common aspects of neurodegenerative pathologies.

Cell Biology and Translational Medicine, Volume 1

  • K. Turksen
  • Biology
    Advances in Experimental Medicine and Biology
  • 2018
ES cells are discussed as a model of development in vitro and as a potential candidate for regenerative medicine and current challenges for ES cell based therapy are dissussed.

New Insights for Oxidative Stress and Diabetes Mellitus

  • K. Maiese
  • Biology
    Oxidative medicine and cellular longevity
  • 2015
The mechanistic target of rapamycin, silent mating type information regulation 2 homolog 1 (S. cerevisiae) (SIRT1), and Wnt1 inducible signaling pathway protein 1 (WISP1) are especially justified to be considered treatment targets for DM.

Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease

  • K. Maiese
  • Biology, Medicine
    Neural regeneration research
  • 2015
Although multiple strategies are being considered, novel targeting of trophic factors, Wnt signaling, WNT1 inducible signaling pathway protein 1, and stem cell tissue regeneration are considered to be exciting prospects to overcome the cellular mechanisms that lead to neuronal injury in diabetes mellitus involving oxidative stress, apoptosis, and autophagy.

mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus.

  • K. Maiese
  • Biology, Medicine
    World journal of diabetes
  • 2015
The pathways of mTOR linked to mTOR complex 1, m TOR complex 2, AMP activated protein kinase, and the hamartin (tuberous sclerosis 1)/tuberin (Tuberousclerosis 2) complex can ultimately influence neuronal, cardiac, and vascular cell survival during oxidant stress in DM through a fine interplay between apoptosis and autophagy.

Feasibility and Efficacy of Intra-Arterial Administration of Embryonic Stem Cell Derived-Mesenchymal Stem Cells in Animal Model of Alzheimer's Disease.

In a rat model of AD, ES-MSCs significantly inhibited Aβ-induced cell death in the hippocampus and promoted autophagolysosomal clearance of Aβ, which was concomitantly followed by decreased levels of A β inThe hippocampus.

Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1–42-infused mouse model of Alzheimer's disease

Data indicate that PD-MSC mediates neuroprotection by regulating neuronal death, neurogenesis, glia cell activation in hippocampus, and altering cytokine expression, suggesting a close link between the therapeutic effects of MSCs and the damaged CNS in Alzheimer’s disease.

Programming apoptosis and autophagy with novel approaches for diabetes mellitus.

  • K. Maiese
  • Biology
    Current neurovascular research
  • 2015
Further elucidation of the ability to translate the roles of WISP1, mTOR, and SIRT1 into effective clinical avenues offers compelling prospects for new therapies against DM that can benefit hundreds of millions of individuals throughout the globe.

Adult Stem Cells

Regardless of their origin, stem cells have the following specific properties: their division and self-renewal capacity over long periods of time, their lack of specification, and their ability to differentiate into specialized cell types.

Stem Cells in Alzheimer's Disease: Current Standing and Future Challenges.

This chapter traces the state of art and the challenges facing the use of stem cells in AD and discusses types of cells, routes and timing of administration, and outcomes of stem cell-based strategies for AD.



Mesenchymal stem cells: new approaches for the treatment of neurological diseases.

MSCs represent a promising new approach to treating diseases of the central nervous system that are traditionally associated with morbid outcomes and with additional pre-clinical and clinical studies that focus on their potential benefits as well as dangers, they may one day find translation to clinical use in the setting of neurological disease.

Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases

These unique properties of MSCs confer on them the potential to be used for therapeutic applications in rheumatic diseases, including rheumatoid arthritis, osteoarthritis, genetic bone and cartilage disorders as well as bone metastasis.

The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells1

It is concluded that the immunosuppressive effect of mesenchymal cells is not confined to multipotent stem cells, but is a fundamental characteristic of all stroma.

Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

The current understanding of MSC biology, mechanism of action in cardiac repair, translational findings, and early clinical trial data of M SC therapy for cardiac disease are reviewed.

Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

The current understanding of the use of genetically engineered mesenchymal stem cells in human disease therapy with emphasis on genetic modifications aimed to improve survival, homing, angiogenesis, and heart function after myocardial infarction is presented.

Bone Marrow‐Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells

Evidence is shown that transplantation of MSCs caused global immunosuppression, as measured by increased CD4+ CD8+ thymocyte production and serum interleukin‐10 and decreased serum interferon‐γ, which implicate the intestine as a new site for MSC tolerance induction and should motivate additional studies evaluating the use of M SCs as a treatment for autoimmune enteropathies.

Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans

  • L. MazziniF. Fagioli E. Madon
  • Medicine, Biology
    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2003
The results appear to demonstrate that the procedures of ex vivo expansion of autologous mesenchymal stem cells and of transplantation into the spinal cord of humans are safe and well tolerated by ALS patients.

Mesenchymal stem cells: clinical applications and biological characterization.

  • F. BarryJ. Murphy
  • Biology, Medicine
    The international journal of biochemistry & cell biology
  • 2004

Roles of db-cAMP, IBMX and RA in Aspects of Neural Differentiation of Cord Blood Derived Mesenchymal-Like Stem Cells

It is shown that MSCs derived from human umbilical cord blood (MSChUCBs) are capable of expressing tyrosine hydroxylase (TH) and Nurr1, markers typically associated with DA neurons, and a possible inhibitory role of the protein kinase A signaling pathway in the phosphorylation of specific TH isoforms is demonstrated.

Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review.

This review focuses on the comparison of two, major, chronic fibroproliferative diseases: the myelofibrosis which develops in bone marrow, a "fluid" tissue producing circulating haematopoietic cells, and liver fibrosis, which demonstrates all the features of solid tissue damage.